594 Introduction: Myelosuppression may be a dose-limiting factor in repeated cycles of
radioligand therapy (RLT). This study aims to investigate the incidence, severity and …

Background Myelosuppression is a potential dose-limiting factor in radioligand therapy
(RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic …

1429 Objectives Radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA)(prostate-
specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. There …

1280 Introduction: Advanced stage metastatic prostate cancer with extensive bone marrow
involvement is related to a high risk of chemotherapy-induced myelotoxicity and poor …

Radioligand therapy with 177 Lu-PSMA-617 is an innovative and effective therapy for
castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone …

Simple Summary Metastatic castration-resistant prostate cancer (mCRPC) with extensive
spread to the bone marrow is an incurable stage of disease associated with a poor …

Simple Summary Radioligand therapy (RLT) with prostate-specific membrane antigen
(PSMA)-directed agents has shown remarkable results in patients with advanced prostate …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

1430 Objectives Radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA)(prostate-
specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. There …

Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …